SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant

Reference:
Product nameSARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
Fragment TypeSpike protein fragment
Aliases /SynonymsB.1.1.529, Omicron variant, lineage B.1.1.529, South Africa variant, Botswana variant
ReferencePX-COV-P074
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

General information on SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant

Lineage B.1.1.529 was reported to WHO in late November 2021 in South Africa. This variant of SARS-CoV-2 accumulates an unprecedented high number of mutations on the spike protein, and especially receptor binding domain (RBD), compared to former variants involved in the Covid-19 pandemic.
The reported mutations are the following : A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211-212, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.
The consequences of these new mutations are not yet clear. Some of them had been detected in other variants. K417N and N501Y are typical mutations of the Beta variant from South Africa. S477N had been reported in a variant found in the USA, detected in December 2020, lineage B.1.526.2. Many other mutations are new to the scientific community and need to be studied. According to preliminary results, this new variant might be related to an increased reinfection rate. There are also evidences for a higher growth of the virus.
The PCR tests that have been deployed for other variants still detect it. The efficiency of market vaccines on the omicron variant is currently studied.
After spreading in all South African regions, the variant has been reported in other African countries such as Botswana and then in Europe.
More studies are necessary to determine the precise properties of this variant, especially the impacts of its unreported mutations on transmissibility and the severity its cases of Severe Acute Respiratory Syndrome.

Reviews

  • Emmanuel

    Worked for our uses. Originally used a free sample but will be ordering more!

REVIEW YOUR PRODUCT

Add a review

Your email address will not be published. Required fields are marked *

Related products

Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1031-SIL 1500€
Stable Istotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1032-SIL 1500€
Stable Istotope Labelled Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1033-SIL 1500€
Stable Isotope Labeled Sotrovimab  Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
Biosimilar Stable Isotope Labeled Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade PX-TA1637-SIL 1500€
Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade
Biosimilar Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade PX-TA1750 400€
Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1797 400€
Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1798 400€
Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1799 400€
Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1800 400€
Anti-RBD-4 antibody (Casirivimab)
Biosimilar Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552 300€
Anti-RBD-5 antibody (Imdevimab)
Biosimilar Anti-RBD-5 antibody (Imdevimab) PTXCOV-A553 300€
Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab)
SIL Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552-SIL 1500€
Anti-2019-nCoV(S1) – 2 (H4) antibody
Monoclonal Antibody Anti-2019-nCoV(S1) – 2 (H4) antibody PTXCOV-A514 300€
Anti-2019-nCoV(S1)-1 IgM antibody
Monoclonal Antibody Anti-2019-nCoV(S1)-1 IgM antibody PTXCOV-A542 380€
ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740)
Receptor ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740) PX-COV-P048 230€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.